NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis

NINDS神经科学卓越网络：加州大学戴维斯分校临床研究站点(PI: Craig M. McDonald， MD；辅助PI:（Michael Rogawski， MD, PhD）该提案通过更新加州大学戴维斯健康系统位于加州萨克拉门托的临床研究站点，为NINDS卓越神经科学网络（NeuroNEXT）做出贡献，萨克拉门托是美国人口最多的州的首府，也是美国最多样化和综合的城市之一。加州大学戴维斯分校NeuroNEXT临床研究站点将继续通过减少神经系统疾病的负担来为NINDS的使命做出贡献。并提供基础设施，以扩大NINDS测试有希望的新疗法的能力，提高临床试验的效率，并在出现新的机会时迅速作出反应，以测试有希望的神经系统疾病患者治疗方法。我们作为现有NeuroNEXT站点的经验、加州大学戴维斯分校（加州大学系统中最全面的校园）卓越的神经科学研究、位于全国公认、经验丰富且具有竞争力的NIH CTSA（加州大学戴维斯分校CTSC）的强大转化研究基础设施、卓越的神经科学研究、来自加州大学加州大学BRAID药物发现联盟的创新合作药物开发管道、国家远程医疗卓越中心的战略定位是促进社区外展，创新信息学，如用于病例识别的Tethered Metadata Registry，以及在具有积极临床附属关系的高排名区域卫生系统中管理的各种神经系统疾病患者的访问，所有这些协同作用使加州大学戴维斯分校继续成为NeuroNEXT网络的杰出临床研究站点。加州大学戴维斯分校NeuroNEXT的目标是：1)利用现有资源和专业知识，作为实施多中心神经科学临床试验的NeuroNEXT中心，提高加州大学戴维斯分校进行试验的效率和质量；2)与加州大学加州分校BRAID药物发现联盟合作，作为NeuroNEXT的核心资源，并作为跨转化领域创新治疗开发的催化剂；3)提供本地和区域社区外展，以改善患者招募和保留，并将社区合作伙伴充分融入转化研究企业；4)有效利用、多样化和利用创新的远程医疗和信息学资源进行临床试验；5)为不同的早期职业研究者提供协作和创新的临床研究培训和支持性环境，以发展额外的研究技能并成为独立的临床研究者。迄今为止，我们在本地、区域和全国取得的成就为未来的成功奠定了良好的基础。

NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis (PI: Craig M. McDonald, MD; Sub‐PI: Michael Rogawski, MD, PhD) This proposal contributes to the NINDS Network for Excellence in Neuroscience (NeuroNEXT) by renewing a clinical research site at the University of California Davis Health System located in Sacramento, CA, the capital of the most populous state in the country and one of the most diverse and integrated cities in the U.S. The UC Davis NeuroNEXT clinical research site will continue to contribute to the mission of NINDS by reducing the burden of neurologic diseases, and contribute an infrastructure which expands the NINDS capability to test promising new therapies, increase the efficiency of clinical trials, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. Our experience as an existing NeuroNEXT site, neuroscience research excellence at UC Davis ‐ the most comprehensive campus in the University of California system, a robust translational research infrastructure housed in a nationally recognized, experienced, and competitively renewed NIH CTSA (the UC Davis CTSC), neuroscience research excellence, an innovative collaborative drug development pipeline from the University of California UC BRAID Drug Discovery Consortium, a national center of excellence in telehealth strategically positioned to promote community outreach, an innovative informatics such as the Tethered Metadata Registry for case identification, and access to diverse patients with neurological disorders managed in a highly ranked regional health system with active clinical affiliations, all work synergistically to position UC Davis to continue to be an outstanding Clinical Research Site for the NeuroNEXT network. UC Davis NeuroNEXT aims to: 1) Leverage existing resources and expertise to serve as a NeuroNEXT hub for implementing multicenter neuroscience clinical trials, increasing the efficiency and quality of trials conducted at the UC Davis site; 2) Collaborate with the University of California UC BRAID Drug Discovery Consortium to serve as a core resource for NeuroNEXT and function as a catalyst for innovative therapeutic development across the translational spectrum; 3) Provide local and regional community outreach to improve patient recruitment and retention and fully integrate community partners into the translational research enterprise; 4) Efficiently utilize, diversify, and leverage innovative telehealth and informatics resources for clinical trials; and 5) Provide collaborative and innovative clinical research training and a supportive environment for diverse early‐career investigators to develop additional research skills and become independent clinical investigators. Our accomplishments to date – locally, regionally, and nationally – provide an outstanding foundation for future success.